Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab versus alpha interferon in Behçet's disease
2014-005390-36Phase 3Unknown
- Sponsor
- University of Liverpool
- Start
- Dec 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in Behçet's disease (BD) comparing Infliximab arm with Alpha interferon arm (2 arms). Primary endpoint: Modified Behçet's Disease Activity Index at 3 months. Status: unknown.
02
Drugs
infliximabinterferon alfa
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on 2014-005390-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005390-36.